Vanda Pharmaceuticals to host conference call Conference call to discuss positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour disorder will be held on January 23 at 9am. Webcast Link
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.
Vanda pullback a buying opportunity, says Piper Jaffray Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.